ARCHIVES

Phase III Regorafenib Trial Meets Endpoint Improving Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 4 | April 27, 2012

Download PDF Visit The Full Archive

Related Articles

NIH Acting Director Kirschstein Preparing For Budget Hearings.

January 14, 2000

Low-Dose Aspirin Cuts Risk Of Colorectal Growths

April 26, 2002

In Sign-Off Of Two Orphan Drugs, ODAC Leaves Efficacy Interpretation To Docs

November 27, 1998

In Brief: Adjuvant Chemotherapy Standard Practice For Breast Cancer At Milan, Bonadonna Says

May 7, 1976

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

September 26, 2014

Abstracts Of Papers From Conference On Adjuvant Therapy

April 22, 1977